2026-09-10 → 09-24 Analyst Bull
Goldman Sachs Resumes RVMD at Buy, PT $267 Goldman resumes biotech coverage with Buy on RVMD, $267 PT
D1 -2.1% · +5d -3.2%
› 2 waves of this story2026-09-10 First coverage with high PT signals confidence in oncology pipeline2026-09-24 Goldman resumes biotech coverage with Buy on RVMD, $267 PT2026-09-11 Insider selling
Insider selling $18.7M (1) D1 +0.2% · +5d -6.3%
8 earlier events › 2026-09-03 Product Bull
NEJM Publishes Phase 1/2 Data on RASONQUE in Metastatic NSCLC Top medical journal publishes key clinical data, boosting product credibility and academic endorsement
D1 +0.8% · +5d -3.4%
2026-08-31 Insider selling
Insider selling $11.4M (1) D1 -1.1% · +5d +0.9%
2026-08-27 Regulation Bull
RVMD Commercializes RASONQUE Post-FDA Nod, Sets Price at $39,800 WAC Onco360 named national pharmacy partner; treatment available as of today with commercial supply and full field teams operational
D1 +2.7% · +5d -4.6%
› 2 waves of this story2026-08-27 First broad RAS-targeted medicine approved for metastatic pancreatic cancer, nearly doubling overall survival2026-08-27 Onco360 named national pharmacy partner; treatment available as of today with commercial supply and full field teams operational2026-08-21 Insider selling
Insider selling $29.9M (2) D1 -1.1% · +5d -0.8%
2026-07-29 → 08-11 Earnings Bull
RVMD Post-Q2 Loss Gets Truist PT Raise to $231 Truist raises PT to $231 from $210, citing newly incorporated opportunities for elironrasib and zoldonrasib
D1 -1.6% · +5d +9.1%
› 6 waves of this story2026-07-29 Company announces Q2 earnings date, providing a key update for investors2026-08-03 Ahead of earnings, institutional buying and investor attention rise2026-08-03 Upcoming earnings release; focus on pipeline progress and financials2026-08-06 Q2 report confirms FDA acceptance of daraxonrasib NDA with priority review; 2,000 patients enrolled in expanded access program2026-08-06 Q2 loss widened and expense outlook raised, while darax launch prep advances with 2,000 patients in expanded access2026-08-11 Truist raises PT to $231 from $210, citing newly incorporated opportunities for elironrasib and zoldonrasib2026-07-23 → 08-06 Regulation Bull
FDA Accepts RVMD's Daraxonrasib Filing for Pancreatic Cancer Earnings reflect continued investment in late-stage programs and commercial prep; analysts expect darax approval by late Aug or early Sept
D1 +3.1% · +5d +1.8%
› 4 waves of this story2026-07-23 Accelerated review brings first commercial product closer for metastatic pancreatic cancer2026-08-03 First Trust raised RVMD stake by 80.3% in Q1, aligning with FDA filing event2026-08-06 Q2 report confirms FDA NDA acceptance; rapid US EAP rollout with 2,000+ patients enrolled2026-08-06 Earnings reflect continued investment in late-stage programs and commercial prep; analysts expect darax approval by late Aug or early Sept2026-08-05 Earnings
Earnings report daraxonrasib在RASolute 302 III期研究中，与化疗相比，在既往治疗过的转移性胰腺癌患者中显示出统计学显著且临床意义重大的总生存期、无进展生存期和患者报告的生活质量改善。
D1 +2.0% · +5d +4.0%
2026-07-23 Regulation Bull
FDA Accepts Daraxonrasib Filing with Accelerated Review for Pancreatic Cancer Accelerated review brings first commercial product closer
D1 +3.1% · +5d +1.8%
› 2 waves of this story2026-07-23 FDA acceptance of NDA for metastatic pancreatic cancer marks key regulatory milestone2026-07-23 Accelerated review brings first commercial product closerby direction · sourced
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
be the first
🙂 Post
Facts and opinions separated · All items sourced · Not investment advice
